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ABSTRACT 
OBJECTIVE: The objective of this systematic review is to determine whether or not 5% 
Imiquimod is more efficacious at sustained treatment of genital warts at 3 months compared to 
1% Imiquimod, ablation, and a placebo vehicle cream. 
 
STUDY DESIGN: Primary literature published between 1996 and the present. 
 
DATA SOURCES: RCT’s were found using Ovid, PubMed, Medline, and Cochrane databases. 
 
OUTCOMES MEASURED: The outcomes measured were a sustained clearance of genital warts 
at 3 months. The outcomes were measured by photographs, measurements, counts, locations, and 
mapping. 
 
RESULTS:  Three RCTs were included in this review. RCTs conducted by Beutner and Edwards 
(separate articles) showed that Imiquimod 5% is superior to most methods including different 
ablation therapies and Imiquimod 1%. One RCT by Schofer showed possibly Imiquimod used in 
combination with ablation may be superior to other treatments.  
 
CONCLUSION: All three RCTs showed that Imiquimod 5% is more effective in clearing genital 
warts and sustaining clearance at 3 months as compared to Imiquimod 1%, ablation, and placebo. 
 
KEYWORDS: Genital warts, HPV, Imiquimod, ablation, and placebo. 
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INTRODUCTION  
 
Genital warts caused by HPV are one of the most common STDs in the world and 
encountered by the medical practitioner. Currently there are many different treatments for genital 
warts including lotions, creams, cryosurgery, ablation, and excision.  
 An estimated 30-50% of sexually active adults are infected with HPV. It is estimated that 
up to 1% actually have genital warts caused by strains 16 and 21. Genital warts that do appear 
will either progress or regress, although this process is not completely understood. Standard 
treatment regimens of excision, ablation, and cryosurgery are only directed at the lesion instead 
of the cause. 
Regression on genital wart and HPV is thought to be due to an immune response, but is 
still widely unknown. Sustained clearance is still relatively random from patient to patient, 
however, it is thought to be improved with immune-response modifiers (Imiquimod). 
There are no approved OTC therapies for the treatment of genital warts caused by HPV. 
Prescription drugs include Imiquimod (Aldara), Podophyllotoxin (Podofilox). Other methods 
include ablation, cryotherapy, excision, and podophyllin resin. 
These prescription drugs are many times successful for the eradication of initial genital 
warts, however, sustained clearance is still difficult to predict.  
OBJECTIVE 
 
The objective of this systematic review is to determine whether or not 5% Imiquimod is 
more efficacious at sustained treatment of genital warts at 3 months compared to 1% Imiquimod, 
ablation, and a placebo vehicle cream. 
 
 
 
 
   Smith: Imiquimod & Sustained Clearance 2 
 
METHODS 
  
Criteria for the selection of studies included healthy men and women 18 years old and 
older. The intervention used was 5% Imiquimod cream with comparisons against 1% Imiquimod 
cream, ablation therapy, and placebo vehicle cream. The outcomes measured were the recurrence 
of genital warts after treatment with the above therapies at 3 months post-treatment. The method 
was to find RCTs with similar inclusion and exclusion criteria. For example all the three RCTs 
used for this systematic review required healthy man and women at least 18 years of age, and 
excluded patients who were imunnosupressed or recently treated for genital warts using the 
treatments in question.  It is of note that each study had additional inclusion and exclusion 
criteria. 
 The types of studies used were RCTs comparing 5% Imiquimod to 1% Imiquimod and 
placebo, 5% Imiquimod and 1% Imiquimod to placebo, and 5% Imiquimod to ablation alone and 
combined. 
 The key words used in this review include genital warts, HPV, Imiquimod, ablation, and 
placebo. All articles were published in English and peer-reviewed. Searches were conducted 
David A Smith using PubMed, Ovid, and Medline. All articles were selected by Patient Oriented 
Evidence that Matters (POEM). All articles had to rely on primary literature published between 
1996 to present, with at least 2 RCTs. All articles had to contain POEMs. Summary of statistics 
reported or used were p-values; RRR; ARR; and NNT. 
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Table 1 - Demographics & Characteristics of Included Studies 
Study  
Type 
 
# 
Patients 
 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Beutner, 
USA, 
1998 
RCT; 
double-
blind; 
parallel-
group 
study 
279 18+ Healthy 
men & 
women, 
>= 2 to 
<= 50 
warts at 
least 
10mm in 
area 
HIV (+); 
Pregnant (+); 
Tx within 4 weeks of 
study; 
Pre-study pap smear 
= HSIL 
72 5% 
Imiquimod; 
1% 
Imiquimod; 
Placebo 
Edwards, 
USA, 
1998 
RCT; 
double-
blind; 
placebo 
controlled 
311 18+ Healthy 
men & 
women, 
>= 2 to 
<= 50 
warts at 
least 
50mm in 
area 
Immunosuppressed; 
HSIL; 
Pregnant or lactating; 
Drug/etoh 
dependency; other 
skin disease; Rx in 
the area within 2 
weeks; wart Tx 
within 4 weeks 
77 5% 
Imiquimod; 
1% 
Imiquimod; 
Placebo 
Schofer, 
Germany, 
2006 
RCT; 3-
arm 
comparison 
377 18+ Healthy 
men & 
women 
with 
external 
genital 
warts up 
to 
2000mm 
area and 
up to 1 
inch 
Previous use of 5% 
Imiquimod within 6 
months; any Tx with 
interferon, 
immunomodulators, 
oral antivirals; 
cytotoxic drugs; 
pregnant or lactating 
women; 
immunocompromised 
91 5% 
Imiquimod;  
Ablation; 5% 
Imiquimod & 
Ablation 
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OUTCOMES MEASURED 
 The outcomes measured were a sustained clearance of genital warts at 3 months. The 
outcomes were measured by photographs, measurements, counts, locations, and mapping. 
RESULTS  
The primary efficacy parameter was based upon all individuals who were completely 
cleared of all genital warts at 12 or 16 weeks and successfully followed up for 3 months.     
Schofer et al reported a sustained clearance of 83.9% for ablation therapy, 93.8% for 5% 
Imiquimod, and 91.7% for ablation and 5% Imiquimod. The difference between 5% Imiquimod 
treatment is statistically significant with p = 0.074. The ARR was calculated to be -0.099 and the 
RRR was -0.615. The NNT was 48. 
 Beutner et al sustained clearance 81% for 5% Imiquimod, 83% for 1% Imiquimod, and 
100% for placebo. The ARR was calculated to be -0.38 and the RR was -0.44. The NNT was -5 
 Edwards et al reported a sustained clearance of 87% for Imiquimod 5%, 100% for 
Imiquimod 1%, and 90% placebo. The ARR was calculated to be 0.3 and the RRR was 0.3. The 
NNT was -8. 
Table 2 - Efficacy of Imiquimod 5% in Sustained Clearance at 3 Months 
Study Imiquimod 
5%  (SCP) 
Imiquimod 
1% (SCP) 
Ablation  
(SCP) 
Placebo 
(SCP) 
C.I. RRR ARR NNT p-
value 
Edwards 
et al 
39/45 
(87%) 
18/18 
(100%) 
N/A 9/10 
(90%) 
NR 0.3 0.3 -8* NR 
Beutner 
et al 
39/48 
(81%) 
10/12 
(83%) 
N/A 100% NR -0.44 -0.38 -5** NR 
Schofer 
et al 
94/100 
(93.8%) 
N/A 77/92 
(83.9%)  
& 
69/75 
(91.7%)* 
N/A NR -0.615 -0.099 48*** 0.074 
*NNT compares Imiquimod 5% to Imiquimod 
**NNT compares Imiquimod 5% to Placebo 
***NNt compares Imiquimod 5% to Ablation & Imiquimod 5% combined treatment 
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SCP = Sustained Clearance Percentage, C.I. = Confidence Interval, RRR = Relative Risk 
Reduction, ARR = Absolute Risk Reduction, NNT = Numbers Needed to Treat 
*91.7 % was recorded with a combination of Imiquimod 5%. 
 
Although all three studies measured total clearance of genital warts over a period of 12 to 
16 weeks, this systematic review was concerned with the sustained clearance of at least 3 months 
of initial genital warts that were measured and removed by the above treatments. All three 
studies reported that 5% Imiquimod had the highest percentage of initial clearance; however, 
sustained clearance did not produce the same results. 
In the studies conducted by Edwards and Beutner 1% Imiquimod and placebo both 
reported a higher percentage of sustained clearance. Schofer reported 5% Imiquimod with the 
highest percentage of sustained clearance. 
Table 3 – Reported Adverse Reaction of Moderate Erythema at Application Site 
Study 5% Imiquimod 1% Imiquimod Vehicle or Ablation 
Beutner et al 40 (43.5%) N/A 8 (8.7%) Vehicle 
Edwards et al 36/106 (34%) 4/106 (4.1%) 3/106 (3.2%) Vehicle 
Schofer et al 56.7% 
55% with ablation 
N/A N/A Ablation 
*Beutner and Edwards reported at 16 weeks (total treatment phase); Schofer reported at 4 
weeks. 
The most common side effect and complaint in all three studies was moderate erythema 
at the application site. It was reported that 40%, 56.7%, and 34% of the 5% Imiquimod group in 
the Beutner et al, Schofer et al, and Edwards et al studies respectively experienced these 
symptoms. The 1% Imiquimod group reported moderate erythema in only 4.1% in the Edwards 
et al study. 
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In all three studies patients were instructed on how to apply 1% Imiquimod, 5% 
Imiquimod, and place vehicle cream. Patients receiving cryotherapy/ablation were treated on an 
outpatient basis. No study had direct supervision of application, other than assessing wart 
clearance at different time intervals. Edwards et al saw patients weekly for the first 2 weeks and 
then biweekly for 16 weeks. Patients who had complete clearance were entered into a 12 week 
follow-up phase. Schofer et al conducted an initial 16 week treatment phase with a 1 month, 3 
month, and 6 month follow-up for those who initially cleared during the treatment phase. In the 
Beutner et al study patients were evaluated weekly for the first 4 weeks and every 2 weeks for 
the 16 week treatment phase. A 12 week follow-up was performed for those patients who had 
initial clearance during the treatment phase. 
DISCUSSION 
 Topical Imiquimod is an immune response modifier that has been shown to exhibit 
antitumor and antiviral properties. It is an imidazoquinolin heterocyclic amine that can increase 
interferon alpha production. Interferon alpha is still very expensive and has been shown to 
effectively treat anogenital warts. 
 Each study had a different modality that proved to be more effective on a percentage 
basis for sustained clearance at 3 months. In the Edwards et al study 5% Imiquimod had a higher 
recurrence rate than that of 1% Imiquimod and placebo cream, however, that may be due to the 
fact that total 5% Imiquimod had more patients in the follow-up phase with 45; while 1% 
Imiquimod had only 18 patients and place cream with 10. 
 The Beutner et al reported that placebo cream had the highest sustained clearance at 3 
months but did not report how many patients were involved in the follow-up phase. In the same 
study 1% Imiquimod reported a higher percentage (83%) than 5% Imiquimod (81%) but again 
   Smith: Imiquimod & Sustained Clearance 7 
 
the 5% Imiquimod group had more patients at 48 compared to 12 patients with the 1% 
Imiquimod group. 
 Finally, the Schofer et al study reported 5% Imiquimod with highest sustained clearance 
compared to ablation and 5% Imiquimod combined with ablation. In this study 5% Imiquimod 
had the highest total of follow-up patients with 100.  
 All three studies were utilized for this systematic review without any significant 
limitations to the studies themselves. 
CONCLUSION 
 The studies reviewed demonstrated that 5% Imiquimod therapy alone is not the most 
effective treatment at sustaining genital wart clearance at 3 months when initially cleared with 
the same therapy. Each study produced a different answer to the proposed hypothesis. At this 
time there is not enough data to support that any one therapy is superior to another in sustaining 
clearance at 3 months. Although 5% Imiquimod is superior in establishing an initial baseline 
clearance of genital warts, an individual’s immune response may play a more vital role in 
sustainment of clearance than supporting initial clearance.  This is impossible to assess since the 
studies do not report the age of participants, only that they have to be at least 18 years old. 
 Ideally the best systematic review would have an equal number of patients in the follow-
up phase with similar ages regardless of therapeutic intervention; however, this may not be 
possible to due to the fact that some treatments are more efficacious than others at establishing 
initial clearance, which mean inevitably the number of patients in follow-up will be skewed.  
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